The B12 addition is a bonus that Wegovy does not include
People 17 years and up (some states require parental consent for 16-year-olds) and those who weigh at least 110 pounds and are in generally good health are eligible to donate in most states
Both Novo Nordisk and Eli Lilly have taken steps to try to lower costs and ease access, such as creating online platforms and offering single-dose vials instead of injector pens
Holding at a dose for an extra 4 weeks before escalating is a medically supported strategy when: Nausea or vomiting persists beyond 2 weeks at the current dose You are unable to eat at least 1,000 calories per day comfortably Dehydration symptoms appear (dark urine, dizziness on standing, dry mouth) You are losing weight faster than 1 to 2 pounds per week on the current dose (aggressive weight loss increases side effect risk) In the STEP trials, delayed escalation did not compromise overall weight loss outcomes at 68 weeks
National Institute For Health And Care Excellence: Semaglutide for managing overweight and obesity PubMed: Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States Business Insider: How weight-loss injections like Ozempic, Mounjaro, and triple G compare in cost, results, and effectiveness FDA Label: OZEMPIC (Semaglutide Injection) Medication Guide FDA Label: WEGOVY (Semaglutide Injection) Medication Guide FDA Label: RYBELSUS (Oral Semaglutide) Medication Guide FDA Label: MOUNJARO (Tirzepatide Injection) Medication Guide FDA Label: ZEPBOUND (Tirzepatide Injection) Medication Guide Important Medical Information and Disclaimers MEDICAL DISCLAIMER This information is for educational purposes only and is not intended as medical advice, diagnosis, or treatment recommendation
